OCB COLOTEST PRODUCT PIPELINE
Disclaimer and Confidentiality
This introductory discussion document is not an inducement or invitation to engage in investment activity [or any kind of commercial collaboration or arrangement]. The sole purpose of this discussion document is to assist recipients in deciding whether they wish to proceed with a further investigation of the proposal. This document is not intended to form the basis of any commercial relationship or investment decision nor of any decision to purchase an interest in the Company. It does not propose to be all-inclusive or to contain all of the information a recipient may require in connection with such evaluation of the Company and, as such, this document is not intended to form the basis of any investment decision or transaction. This document does not constitute an offer or invitation for the sale or purchase of securities and is not a prospectus.

The contents of this document have been prepared from information provided by various sources and has not been independently verified by any party and no due diligence has been conducted. No representation or warranty, express or implied, is or will be made in relation to, and no responsibility or liability is or will be accepted by any party whatsoever, including the current owners, or by any of their officers, servants or agents as to, or in relation to, the accuracy or completeness of this document or any of the information contained herein or to any other written or oral information made available to any interested party or its advisers, and any liability therefore is hereby expressly disclaimed. Only those particular representations and warranties, if any, which may be made in any subsequent legally binding written agreement (which will not contain any representations or warranties, if any, as to this document) when and if it is finally executed, and subject to such limitations and restrictions as may be agreed, shall have any legal effect.

Certain statements included in this document may constitute forward-looking statements that involve a number of risks and uncertainties. All of these forward-looking statements are based on estimates and assumptions, although believed to be reasonable, are inherently uncertain. The recipient is cautioned that these forward-looking statements are subject to risks, uncertainties and other factors that could cause actual results to differ materially from future results expressed or implied by such forward-looking statements. Important factors that may cause actual results to differ materially from the information set forth in any forward-looking statements include, without limitation, the effect of general economic conditions, increases in competition in the industry in which the company operates, changes in technology, customer actions, government regulation and tax matters etc.
Oxford Cancer Biomarkers (OCB) 
Background & Mission

- OCB spun out of Oxford University in 2012 from the laboratories of Nick La Thangue (Professor of Cancer Biology) and David Kerr (Professor of Cancer Medicine) to advance personalised medicine for oncology.

- The company is closely affiliated with the University of Oxford, where its founders lead research groups focused on translational cancer science.

- OCB develops and commercialises biomarker tests that enable more effective treatment for patients.

- Since 2014 focus on ColoTest platform of tests to determine risk of disease and of improve outcomes for patients with colorectal cancer (CRC)

- Mission to improve cancer treatment decisions:
  - Increased benefit, less toxicity and cost effective

- Using our biomarker tests can provide more effective treatment for patients and economic savings for the healthcare systems.
CRC tests - improving clinical practice

- Colorectal cancer:
  - 2nd most common in women and 3rd most common cancer in men.
  - 1.4 million newly diagnosed patients each year worldwide
  - Annual costs in EU > €13bn (10% of total cancer related costs)
  - 41,804 new cases in the UK in 2015 (12% of total)

![Graph showing the rate per 100,000 people per year from 1971 to 2016 for colorectal cancer cases by gender and type.](image)

<table>
<thead>
<tr>
<th>Year</th>
<th>Male</th>
<th>Female</th>
<th>Persons</th>
</tr>
</thead>
<tbody>
<tr>
<td>1971</td>
<td>15</td>
<td>5</td>
<td>20</td>
</tr>
<tr>
<td>1972</td>
<td>20</td>
<td>6</td>
<td>26</td>
</tr>
<tr>
<td>1973</td>
<td>25</td>
<td>7</td>
<td>32</td>
</tr>
<tr>
<td>1974</td>
<td>30</td>
<td>8</td>
<td>38</td>
</tr>
<tr>
<td>1975</td>
<td>35</td>
<td>9</td>
<td>44</td>
</tr>
<tr>
<td>1976</td>
<td>40</td>
<td>10</td>
<td>50</td>
</tr>
<tr>
<td>1977</td>
<td>45</td>
<td>11</td>
<td>56</td>
</tr>
<tr>
<td>1978</td>
<td>50</td>
<td>12</td>
<td>62</td>
</tr>
<tr>
<td>1979</td>
<td>55</td>
<td>13</td>
<td>68</td>
</tr>
<tr>
<td>1980</td>
<td>60</td>
<td>14</td>
<td>74</td>
</tr>
<tr>
<td>1981</td>
<td>65</td>
<td>15</td>
<td>80</td>
</tr>
<tr>
<td>1982</td>
<td>70</td>
<td>16</td>
<td>86</td>
</tr>
<tr>
<td>1983</td>
<td>75</td>
<td>17</td>
<td>92</td>
</tr>
<tr>
<td>1984</td>
<td>80</td>
<td>18</td>
<td>98</td>
</tr>
<tr>
<td>1985</td>
<td>85</td>
<td>19</td>
<td>104</td>
</tr>
<tr>
<td>1986</td>
<td>90</td>
<td>20</td>
<td>110</td>
</tr>
<tr>
<td>1987</td>
<td>95</td>
<td>21</td>
<td>116</td>
</tr>
<tr>
<td>1988</td>
<td>100</td>
<td>22</td>
<td>122</td>
</tr>
<tr>
<td>1989</td>
<td>105</td>
<td>23</td>
<td>128</td>
</tr>
<tr>
<td>1990</td>
<td>110</td>
<td>24</td>
<td>134</td>
</tr>
<tr>
<td>1991</td>
<td>115</td>
<td>25</td>
<td>140</td>
</tr>
<tr>
<td>1992</td>
<td>120</td>
<td>26</td>
<td>146</td>
</tr>
<tr>
<td>1993</td>
<td>125</td>
<td>27</td>
<td>152</td>
</tr>
<tr>
<td>1994</td>
<td>130</td>
<td>28</td>
<td>158</td>
</tr>
<tr>
<td>1995</td>
<td>135</td>
<td>29</td>
<td>164</td>
</tr>
<tr>
<td>1996</td>
<td>140</td>
<td>30</td>
<td>170</td>
</tr>
<tr>
<td>1997</td>
<td>145</td>
<td>31</td>
<td>176</td>
</tr>
<tr>
<td>1998</td>
<td>150</td>
<td>32</td>
<td>182</td>
</tr>
<tr>
<td>1999</td>
<td>155</td>
<td>33</td>
<td>188</td>
</tr>
<tr>
<td>2000</td>
<td>160</td>
<td>34</td>
<td>194</td>
</tr>
<tr>
<td>2001</td>
<td>165</td>
<td>35</td>
<td>200</td>
</tr>
<tr>
<td>2002</td>
<td>170</td>
<td>36</td>
<td>206</td>
</tr>
<tr>
<td>2003</td>
<td>175</td>
<td>37</td>
<td>212</td>
</tr>
<tr>
<td>2004</td>
<td>180</td>
<td>38</td>
<td>218</td>
</tr>
<tr>
<td>2005</td>
<td>185</td>
<td>39</td>
<td>224</td>
</tr>
<tr>
<td>2006</td>
<td>190</td>
<td>40</td>
<td>230</td>
</tr>
<tr>
<td>2007</td>
<td>195</td>
<td>41</td>
<td>236</td>
</tr>
<tr>
<td>2008</td>
<td>200</td>
<td>42</td>
<td>242</td>
</tr>
<tr>
<td>2009</td>
<td>205</td>
<td>43</td>
<td>248</td>
</tr>
<tr>
<td>2010</td>
<td>210</td>
<td>44</td>
<td>254</td>
</tr>
<tr>
<td>2011</td>
<td>215</td>
<td>45</td>
<td>260</td>
</tr>
<tr>
<td>2012</td>
<td>220</td>
<td>46</td>
<td>266</td>
</tr>
<tr>
<td>2013</td>
<td>225</td>
<td>47</td>
<td>272</td>
</tr>
<tr>
<td>2014</td>
<td>230</td>
<td>48</td>
<td>278</td>
</tr>
</tbody>
</table>

Proportion of Cases Diagnosed at Each Stage, All Ages (England 2014)

<table>
<thead>
<tr>
<th>Stage</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>15</td>
</tr>
<tr>
<td>II</td>
<td>23</td>
</tr>
<tr>
<td>III</td>
<td>26</td>
</tr>
<tr>
<td>IV</td>
<td>22</td>
</tr>
<tr>
<td>Unknown</td>
<td>13</td>
</tr>
</tbody>
</table>

Five-Year Relative Survival (%) by Stage Adults Aged 15-99

<table>
<thead>
<tr>
<th>Stage</th>
<th>Survival (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>97.4</td>
</tr>
<tr>
<td>II</td>
<td>84.7</td>
</tr>
<tr>
<td>III</td>
<td>62.65</td>
</tr>
<tr>
<td>IV</td>
<td>59.65</td>
</tr>
<tr>
<td>All Stages</td>
<td>16.9</td>
</tr>
<tr>
<td>Unknown</td>
<td>16.9</td>
</tr>
</tbody>
</table>

1. GLOBOCAN 2012 Colorectum Factsheet http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx
CRC tests - improving clinical practice

- Incidence rates in the UK have remained stable since the early 1990s
- Survival is improving and has more than doubled in the last 40 years in the UK.
- Preventability estimates using the findings from the Continuous Update Project (WCRFI) show that about 45 per cent of cases of colorectal cancer in the UK can be prevented by lifestyle changes

- Clinical questions addressed by OCB’s CRC biomarker tests:
  - who is most at risk from developing CRC?
  - will disease reoccur post surgery?
  - is the patient likely to have severe drug toxicity?

- Delivering a new standard-of-care:
  - right patient, right drug, right time, right cost
What technology underpins OCB’s tests?

- **ToxNav and ColoPredict**
  - genetic variation in important genes
  - DNA sequencing platform

- **ColoProg**
  - tumour morphology
  - DNA damage

- **Read-out from tests**
  - provides a measure of risk
Precision diagnostic CRC tests – providing a new standard of care

Population screen for CRC prediction

ColoPredict

- 80% patients have surgical resection

ColoProg

- 40 - 50% low risk of recurrence
- 15% high risk of recurrence

ToxNav

- High risk of toxicity: Modulate dose
- Low risk of toxicity: Standard dose

Risk of developing disease
(n = 42,103 individuals)
WORK ONGOING

Risk of recurrence
(n = 2,624 patients)
DANIELSEN ET AL, ANNALS OF ONCOLOGY 2018

Toxic response to drug
(n = 888 patients)
MANUSCRIPT IN DRAFT
An innovative germline DNA test which predicts genetic susceptibility to severe toxicity following treatment with 5FU/capecitabine.
5FU-associated toxicity in CRC patients

- 5FU/Capecitabine is currently used as first line treatment for tens of thousands of colorectal cancer cases each year in the UK.

- Toxicities are a burden to patients’ quality of life and their carers and comes at a high financial burden to commissioners and health economies.

- Side effects include:
  - Neutropenic sepsis,
  - Diarrhoea,
  - Nausea/vomiting,
  - Stomatitis,
  - Hand-foot syndrome (HFS).
ToxNav Background

- ToxNav measures the risk of high grade toxicity associated with treatment of colorectal cancer with fluoropyrimidine-based chemotherapy (5FU/capecitabine).

- Based on three key studies (GWAS and meta-analysis):
  - Rosmarin et al, Gut 2014: A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS.

- Patent filed March 2014, GB, EU, USA, China, India, Hong Kong

- IP licenced from Oxford University July 2015

- ToxNav UK partnership in place with Source Bioscience.
ToxNav Description

- ToxNav determines genotypes of 21 genetic variants (SNPs) associated with toxicity.

- Platform agnostic, Sanger sequencing currently used for genotyping

- Patients are stratified into categories informing on risk of toxicity:
  - Critical risk
  - High risk
  - Standard risk
  - Standard risk * High Risk HFS

- ToxNav provides clinicians and patients with information that can help assist in the choice of chemotherapy treatment regimens after initial surgery.

- CE mark obtained February 2017.

- Health economic assessment ongoing.
ToxNav Risk Reporting

- The likely DYPD phenotype is based on the genotype as determined by sequencing using the following guidelines based on information outlined in the original CPIC DPYD Guidelines (Caudle et al, Clinical Pharmacology and Therapeutics, 2013*)

<table>
<thead>
<tr>
<th>Risk Level</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Critical RISK</td>
<td>• Variants present that would likely indicate DPD Deficiency. • 5FU/Capecitabine containing therapy is contraindicated and should not be administered as stated on the drug label.</td>
</tr>
<tr>
<td>High RISK</td>
<td>• Variants detected are strongly associated with partial DPD Deficiency. • Patient has at least 2x the risk of grade 3/4 toxicity using a standard dose of 5FU/Capecitabine. • 5FU/Capecitabine dose modulation of 50% is recommended.</td>
</tr>
<tr>
<td>Standard RISK</td>
<td>• No increased risk of grade 3/4 toxicity to patients when using a standard dose of 5FU/Capecitabine or 5FU monotherapy. • 5FU/Capecitabine dose of 100% is recommended unless the clinician feels that there are other factors which would mitigate dose.</td>
</tr>
<tr>
<td>Standard RISK *</td>
<td></td>
</tr>
<tr>
<td>High Risk HFS</td>
<td>• No increased risk of grade 3/4 toxicity to patients using a standard dose of 5FU/Capecitabine. • *There is a high risk of HFS, this risk is at least 2x the risk of the Standard Risk Population. • 5FU/Capecitabine dose of 100% is recommended. Advice on how to minimise/prevent HFS according to local guidelines is recommended.</td>
</tr>
</tbody>
</table>

*Updated in 2018
ToxNav test procedure steps 1-7

1. Patients offered fluoropyrimidine chemotherapy
   • ToxNav test requested by clinician via OCB website

2. Blood sample taken (EDTA)
   • Sample requisition form received and logged by laboratory

3. Sample and requisition form received and logged by laboratory
   • DNA extracted

4. Sanger sequencing carried out to detect genotype of 21 variants
   • Data managed via secure server

5. Results transmitted from lab to OCB analysis suite
   • Data imported to ToxNav software

6. Risk category designated
   • Standard Risk
   • High Risk
   • Critical Risk
   • Standard Risk “HFS”
   • Results verified by OCB clinician
   • ToxNav clinical risk report generated

7. ToxNav Report received by clinician and risk category discussed with patient
   • Chemotherapy decision made
A prognostic marker for colorectal cancer: combining analyses of ploidy and stroma.
Treatment of Stage II CRC patients

- Adjuvant treatment can be an ‘easy’ decision in stage III CRC (although III A has a better prognosis than stage II !) but there is clinical controversy as to whether treatment should be offered to stage II CRC patients.

- Patients (and their doctors) would like to know the chance of cancer recurrence as this dictates follow-up and potential benefit from adjuvant chemotherapy.

- A number of tools are already available and used for selecting patients e. g.
  - T stage,
  - Grade,
  - Invasion,
  - Margin status,
  - No. lymph nodes,
  - Mismatch repair (MMR),
  - Microsatellite instability (MSI) status, etc.

- BUT no molecular markers have so far been routinely established in clinical practice to predict treatment benefit for Stage II patients.

- Currently, around 50-60 % of Stage II CRC patients receive adjuvant chemotherapy, a proportion of which is administered in combination, potentially over treating the general population of patients so that a small minority might benefit.
ColoProg Introduction

• ColoProg determines the prognosis of Stage II colorectal cancer patients after treatment with fluoropyrimidine-based chemotherapy.

• Utilises digital pathology to examine specimens in order to determine DNA ploidy and tumour stroma content.

• Biomarkers are combined to stratify patients into categories informing on risk of recurrence:
  • High Risk (non-diploid and high stroma).
  • Intermediate risk (non-diploid and low stroma OR diploid and high stroma).
  • Low risk (diploid and low stroma).

• ColoProg provides clinicians and patients with information, that together with other relevant clinical parameters such as co-morbidities and performance status, can help assist in the choice of chemotherapy treatment regimens after initial surgery.
ColoProg - Sample analyses

**Ploidy digital analyses**
- Sample classified diploid when DNA content 2N.
- Sample classified tetraploid (non-diploid) when DNA content 4N or higher.
- 4N content significant even when at low levels.

**Stroma digital analyses**
- Pink: epithelial (tumour) tissue (H&E stain).
- Green: stroma tissue.
- Imaging software assigns false colour to stroma portion of tissue and uses this to calculate percentage stroma present in sample.

Non-diploid = high risk
Diploid = low risk

Stroma high ≥ 50% = high risk
Stroma low < 50% = low risk
ColoProg Reporting (Example)

ColoProg Results:

ColoProg Designation: non-diploid (ND) low stroma (L)

Risk Categorization:

Ploidy

ND

D

Stroma

L

H

Risk of recurrence

0 26 50 100

Low  High

HIGH

INTERMEDIATE

INTERMEDIATE

LOW
ColoProg test procedure steps 1-6:

1. Patient receives surgery
2. Formalin fixed paraffin embedded (FFPE) tissue used for pathology
3. Treatment discussed with patient
4. ColoProg test requested by clinician via OCB website
   - FFPE slide sent to OCB laboratory
   - Sample and requisition form received and logged by laboratory
   - Tumour sample processed for stroma and ploidy analysis
   - Digital image analysis carried out for
     - Stroma (tumour image analysis)
     - Ploidy (DNA content determination)
   - Stroma and ploidy data combined to produce risk category designation
   - Final data set approved by pathologist
5. Risk category designated
   - Low Risk
   - Intermediate Risk
   - High Risk
   - Results verified by OCB clinician
   - ColoProg clinical risk report generated
6. ColoProg Report received by clinician and recommendation discussed with patient
   - Chemotherapy decision made
ColoProg Clinical Validation Study Design

• Combined colorectal cancer data set (2624 patients):
  • QUASAR2 trial (UK) 1092
  • Aker cohort (Oslo) 954
  • Gloucester cohort (UK) 578
  N.B. combined number of Stage II patients = 1029

<table>
<thead>
<tr>
<th>DNA ploidy</th>
<th>Tumour stroma</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Nuclei isolated from tumour region of FFPE sections</td>
<td>1. FFPE section H&amp;E stain</td>
</tr>
<tr>
<td>2. Feulgen basic fuschin staining method</td>
<td>2. Tumour area confirmed by pathologist</td>
</tr>
<tr>
<td>3. Digital microscopy to determine DNA content</td>
<td>3. Digital pathology to determine stroma content</td>
</tr>
<tr>
<td>4. Tumours classified as diploid (D) or non-diploid (ND)</td>
<td>4. Tumours assigned: stroma low (≤50%) or stroma high (&gt; 50%)</td>
</tr>
</tbody>
</table>
ColoProg Clinical Validation

• Utilises digital pathology to examine specimens using proprietary algorithms to determine DNA ploidy and tumour stroma content.

• Biomarkers are combined to stratify patients into categories informing on risk of recurrence.

• Initially validated using the QUASAR2 clinical trial and two other studies (total patient number = 2624) and allows Stage II CRC patients to be classified into low, intermediate and high risk groups.
ColoProgs: Risk Stratification

Stage II patients can be stratified into low vs high risk groups using DNA ploidy and stroma classification (total n=2624, Stage II n=1029)

Figure 1: Kaplan-Meier plot illustrating cancer-specific survival (CSS) for patients with tumours that were diploid and low stroma (D and LS), diploid and high stroma or non-diploid and low stroma (D and HS/ND and LS), and non-diploid and high stroma (ND and HS) among patients with stage II tumours.

ColoProg Clinical Validation: Conclusions

• High risk Stage II patients:
  • Can be divided into risk groups based on a combination of measurements of DNA ploidy and stroma.

• Automated digital pathology could facilitate adoption of biomarker analyses into patient treatment strategies.

• **END GOAL**: production of a prognostic test that can be offered to patients to inform the use of adjuvant treatment after surgery.
COLOPREDICT™

A test performed on a DNA sample in normal people invited to participate in screening programme to determine lifetime risk of developing colorectal cancer.
ColoPredict™ Introduction

- **ColoPredict™**: A population-based test that measures a person’s risk of developing CRC.
- **Validation**: currently validated in a cohort of 51,000 people and results published in world leading journals.
- **Aim**: to identify populations of normal individuals at high risk (5-10x risk greater than average) of developing CRC:
  - Allowing patients to adapt their lifestyle appropriately and undergo more intensive surveillance.
- **Improved screening strategies**: good evidence that screening shifts detection of CRC to early stage (Stages 1 and 2 as opposed to Stages 3 and 4), and dramatically improves patient survival and decreases the cost of treatment.
- **Enhancing current screening programs**: ColoPredict™ is seen as complementary to and not a replacement for any of the current faecal tests which are used for CRC screening.
- There are no genetic tests of this type currently available which have undergone the same standard of clinical validation as ColoPredict™.
ColoPredict™ Validation and Delivery

- ColoPredict™ consists of an algorithm of highly validated SNPs associated with lifetime risk of CRC.
- SNPs identified from an extensive Genome Wide Association Study of 48,576 European subjects (26,660 CRC cases and 21,916 cancer free controls).
- The risk scores can also be combined with additional risk factors such as family history of CRC, the incorporation of family history and SNP algorithms has been previously published as an effective way to identify those at the greatest risk.

**ColoPredict™ test procedure:**

1. **CRC screening kit is sent to each patient for sample collection**
   - Standard FOBT Kit
   - DNA Specimen Collection Kit (one-off buccal swab)
   - DNA sample is sent to a central lab for analysis.

2. **DNA sample and requisition form received and logged by laboratory**
   - DNA extracted

3. **Sanger sequencing carried out to detect genotype of risk variants**
   - Data managed via secure server

4. **Results transmitted from lab to OCB analysis suite**
   - Data imported to ColoPredict™ software

5. **Patient receives notification of eligibility for national CRC screening programme**

6. **Patient risk report including advice returned to each individual and their GP at the same time as FOBT results.**
ColoPredict™ clinical validation

A germline DNA test to assess genetic susceptibility to lifetime risk of colorectal cancer

- Genome Wide Association Study (GWAS): 44,389 Europeans (24,395 CRC cases, 19,994 cancer-free controls).
- Estimates suggest 100 variants account for majority of genetic risk.
- Currently 20 variants described by test, 10 of which are in the public domain.
- The test checks for 40 alleles generating a score for increased lifetime CRC risk.

FH+ = Family history known and is used to stratify high risk individuals

Data from Dunlop et al (2012), Gut.
Contact

• For further information, please contact
  • info@oxfordbio.com
  • +44 1865 784743

See us at

• www.oxfordbio.com
• @OCBiomarkers
• LinkedIn: https://www.linkedin.com/company/oxford-cancer-biomarkers/